Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Decision Resources Group
In the news release, U.S. Market for Neurostimulation Devices Will Reach Almost $4 Billion by 2022, issued 09-Apr-2014 by Decision Resources Group over PR Newswire, we are advised by the company that the first paragraph, second sentence, should read "NeuroPace's responsive stimulation device" rather than "NeuroPace's deep brain stimulation (DBS) device" as originally issued. The complete, corrected release follows:
BURLINGTON, Mass., April 9, 2014 /PRNewswire/ -- Decision Resources Group finds that the approval of new indications-particularly chronic heart failure, obesity and epilepsy-will expand the patient pool and market potential for neurostimulation devices in the United States considerably, allowing the market to reach a value approaching $4 billion by 2022. Most notably, because neurostimulation is already well accepted as a treatment for epilepsy, the Food and Drug Administration's (FDA) approval in 2013 of NeuroPace's responsive stimulation device for this indication will lead to rapid adoption of this product.
Other key findings from the Medtech 360 report entitled US Markets for Neurostimulation Devices 2014:
Comments from Decision Resources Group Analyst Roald Dhoska:
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.